Format

Send to

Choose Destination
Ann Hematol. 2003 Feb;82(2):80-82. doi: 10.1007/s00277-002-0599-4. Epub 2003 Feb 11.

Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis.

Author information

1
Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Av. S.A.M. Claret 167, 08025, Barcelona, Spain. msubira@hsp.santpau.es.
2
Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Av. S.A.M. Claret 167, 08025, Barcelona, Spain.
3
Department of Hematology, Hospital Clínico, Barcelona, Spain.
4
Department of Hematology, Hospital Clínico, Salamanca, Spain.
5
Unit of Bone Marrow Transplant, Hospital Gregorio Marañon, Madrid, Spain.
6
Department of Hematology, Hospital de La Princesa, Madrid, Spain.

Abstract

Diagnosis of invasive pulmonary aspergillosis (IPA) is often difficult. Recently, the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) has proposed new criteria for the classification of invasive fungal infections. We have studied the clinical applicability of this classification in 22 patients with hematological malignancies who had IPA at autopsy. While alive, according to the EORTC/MSG criteria, only 2 patients were classified as having proven IPA, 6 as probable, 13 as possible, and 1 was unclassifiable. Of the patients, 64% had no microbiological or major clinical criteria before death. Although the EORTC/MSG criteria are an important step forward in the standardization of definitions used for IPA in clinical research studies, most patients who die with extensive lung disease only reach a level of possible or probable IPA during life, further highlighting that these guidelines should not be used for clinical decision-making.

PMID:
12601484
DOI:
10.1007/s00277-002-0599-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center